linjc16/ctgov huggingface dataset:
Treatment for Post-Stroke Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate a program of education, medicine, and monitoring for the treatment of depression after a stroke.

Detailed Description
-----------------
This trial will compare outcomes in depressed patients receiving the Activate-Initiate-Monitor (AIM) intervention vs. those receiving usual care, and will also compare outcomes in depressed and non-depressed stroke survivors. Patients are screened for depression 1 to 2 months post-stroke. Patients with depression are then randomized to the AIM intervention or control group. Patients without depression are also enrolled at the same time and are matched by hospital site to the depressed patients. The AIM intervention is a 3-part program consisting of activating or educating the patient and his/her family about post-stroke depression, instituting treatment for depression, and monitoring antidepressant treatments for side effects, efficacy, and compliance. Control patients are evaluated and treated with usual care by their physicians. Patients without depression do not receive the intervention but complete the same assessments on the same schedule as the patients with depression.

Official Title
-----------------
Treatment for Post-Stroke Depression

Conditions
-----------------
Stroke, Depression

Intervention / Treatment
-----------------
* Other: case management


Participation Criteria
=================
Eligibility Criteria
-----------------
No severe language or cognitive deficits, life expectancy of at least 9 months, and willingness to participate.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nurse Case management<br> | Other: case management<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Twelve Week Depression Outcomes | Depression remission was defined as HAM-D less than 8 or HAM-D decreased by 50%. The Hamilton Rating Scale for Depression is measured on a scale from no depression - major depression, 0-52 units on a scale. | Twelve week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke, depression
Causes of Chronic Pruritus

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to include all patients followed between 2008 and 2018 in order to analyze the etiologie of the chronic pruritus

Official Title
-----------------
Causes of Chronic Pruritus: a Retrospective Study

Conditions
-----------------
Chronic Pruritus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than 18 years old In patient in a day hospital or longer hospitalization in the dermatology department With chronic pruritus which means pruritus longer than 6 weeks without skin lesions specific to pruritic dermatitis. Exclusion Criteria: Itchy dermatose Refusal to particpate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Causes of chronic pruritus | Analyze the etiology of chronic pruritus : uremic pruritus, cholestatic pruritus, haematologic pruritus, metabolic pruritus, neuropathic pruritus, psychogenic pruritus, idiopathic pruritus thanks to results of biological parameters, Imaging data, clinical data (for example consultation with psychiatric for psychogenic pruritus) | through study completion, an average of 1 year |
Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and tolerability of the combination chemotherapy of DICE in the patients with NK/T cell lymphoma.

Detailed Description
-----------------
Patients with NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy of CHOP.The investigators did this trial to evaluate the efficacy and tolerability of the combination chemotherapy of DICE in the patients with NK/T cell lymphoma.

Official Title
-----------------
Phase II Study of a Combination Chemotherapy of DICE in the Patients With NK/T Cell Lymphoma

Conditions
-----------------
Lymphoma

Intervention / Treatment
-----------------
* Drug: IFO, VP-16, DDP, DXM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age range 18-75 years old Histological confirmed NK/T cell lymphoma ECOG performance status less than 2 Life expectancy of more than 3 months None of major drugs in the trial (IFO,VP16,DDP) has been previously used Normal laboratory values: hemoglobin > 80 g/dl, neutrophil > 2×109/L, platelet > 100×109/L, serum creatine < 1.5×upper limitation of normal (ULN), serum bilirubin < 1.5×ULN, ALT and AST < 2.5×ULN Exclusion Criteria: Pregnant or lactating women Serious uncontrolled diseases and intercurrent infection The evidence of CNS metastasis History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IFO, VP-16, DDP, DXM<br> | Drug: IFO, VP-16, DDP, DXM<br>* DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.<br>* Other names: DICE;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate |  | every two cycles | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TTP and OS |  | every two cycles | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NK/T cell lymphoma, Response Rate, TTP, OS, Toxicities
Inspiratory Muscle Training in Pulmonary Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is evaluate the effect the inspiratory muscle training on the functional capacity of patients with pulmonary hypertension.

Detailed Description
-----------------
Pulmonary hypertension (PH) is a syndrome, in the case of hemodynamic alteration of a number of diseases and processes, such as the progressive increase in pulmonary vascular resistance, right heart failure and early death. Frequently patients with PH have reduced functional capacity, quality of life and survival. It was demonstrated recently that patients with HP also have inspiratory muscle weakness, possibly further increase the fatigue and dyspnea during exercise. To meet this need, inspiratory muscle training can lead to significant improvement in respiratory muscle strength, exercise tolerance and dyspnea, thus resulting in reduction of discomfort during activities of daily living, increase in exercise capacity and improved quality of life in different situations.

Official Title
-----------------
Inspiratory Muscle Training Effect on the Functional Capacity and the Quality of Life in Chronic Pulmonary Hypertension

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: Inspiratory muscle training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis pulmonary hypertension World Health Organization (WHO) functional class II to IV inspiratory muscle weakness Exclusion Criteria: obesity chronic obstructive pulmonary disease orthopedic and neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The distance traveled in meters in the six minutes walk test after 8 weeks the inspiratory muscle training |  | patients will be monitored throughout the training protocol for 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in score of quality of life questionnaire after 8 weeks the inspiratory muscle training |  | patients will be monitored throughout the training protocol for 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pulmonary hypertension, inspiratory muscle training, inspiratory muscle weakness, pulmonary functional, functional capacity, quality of life
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

Study Overview
=================
Brief Summary
-----------------
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.

Official Title
-----------------
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

Conditions
-----------------
Chronic Idiopathic Urticaria

Intervention / Treatment
-----------------
* Drug: Omalizimab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of chronic idiopathic urticaria for 3 months failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin Exclusion Criteria: physical or cholinergic urticaria past treatment in Omalizumab i nprevious year parasitic infection malignancy in last 5 years known sensitivity to Omalizumab

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Omalizumab<br>Omalizimab 150 mg S.C. once a month for consecutive 3 months | Drug: Omalizimab<br>* Omalizimab 150 mg S.C. once a month for consecutive 3 months<br>* Other names: Xolair;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS) |  | 3 months |
Japan Central Aortic Pressure Prospective Study

Study Overview
=================
Brief Summary
-----------------
Purpose of the study The predictive value of central aortic pressure and aortic pulse wave velocity (PWV) in a Japanese population is not known. The purpose of this study is to quantify the predictive value of these indices in the determination of cardiovascular risk. Recently, a non-invasive method to separate the aortic pressure waveform into the separate ejection pressure wave and reflected pressure wave has become available. With this decomposition method, it is possible to estimate aortic PWV (named AVI). The second objective of this study is to determine if AVI can be a substitute for carotid-femoral PWV (cf-PWV), the current gold standard for aortic PWV measurement. To study vascular aging of the Japanese population by evaluating central blood pressure and aortic PWV by age, and compare these values to similar studies done in Caucasian and Chinese patient populations. To study the relationship between the magnitude of the aortic reflected pressure wave and the degree of left ventricular (LV) hypertrophy and LV diastolic function.

Official Title
-----------------
Central Blood Pressure Follow-up Study in Japanese

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who visit hospital for their health checks Healthy volunteers who agree to participate in this study Exclusion Criteria: History of coronary artery disease, cerebrovascular disease, congestive heart failure, aortic dissection Subjects taking vasoactive drugs (antihypertensive and/or nitrates) Atrial fibrillation or atrial flutter Renal dysfunction (serum creatinine ≥3 mg/dl) Type I diabetes mellitus Hepatic dysfunction (AST and/or ALT ≥100 IU/l) A history of malignant tumor within 5 years of enrollment or suspected Pregnancy, possible pregnancy Chronic inflammation disease Not suited to the clinical trial as judged by a collaborating physician Inability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| •Composite of following events: sudden death, cardiovascular death, stroke, coronary events, heart failure |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New onset of hypertension, diabetes mellitus, or atrial fibrillation |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Central aortic pressure, Aortic pulse wave velocity, Aortic PWV using a single pressure recording, Vascular aging, Left ventricular hypertrophy, Left ventricular diastolic function
SD01 Master Study (Safety and Efficacy Study)

Study Overview
=================
Brief Summary
-----------------
The study is designed to confirm safety and efficacy of the SD01 ICD (implantable cardioverter-defibrillator) lead.

Official Title
-----------------
SD01 Master Study (Safety and Efficacy Study)

Conditions
-----------------
Ventricular Tachycardia, Ventricular Fibrillation, Heart Failure

Intervention / Treatment
-----------------
* Device: SD01 ICD lead


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Standard indication for an ICD/CRT-D therapy Signed informed consent form Patient is willing and able to participate for the whole study duration Patient is willing and able to activate and use the CardioMessenger Legal capacity and ability to consent. Exclusion Criteria: Standard contraindication for an ICD/CRT-D therapy Age <18 years. Pregnant or breastfeeding Cardiac surgery is planned within the next six months Any condition that in the opinion of the investigator would preclude compliance with the study protocol during the whole follow-up period Enrollment in another cardiac clinical investigation with active treatment arm Mechanical tricuspid valve prosthesis or severe tricuspid valve disease Dexamethasone acetate intolerance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: SD01 ICD lead|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of appropriate sensing and pacing | The evaluation of right ventricular sensing performance is based on the assessment of consecutive intrinsic beats documented with markers on an IEGM (intra-cardiac electrogram). The evaluation of ventricular sensing performance is based on the data to be collected during the 3-month follow-up. The appropriate pacing performance in the right ventricle results from the evaluation of capture at the end of the 3-month follow-up. | at the 3-month follow-up | 
| Serious adverse device effects (SADEs) related to the SD01 lead |  | until the 3-month follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of pacing threshold between Linoxsmart and SD01 | Comparison of the manually measured pacing threshold of the SD01 lead system to the Linox SD lead at 3-month follow-up. The idea is that the pacing threshold will be similar within a suitable range. | at the 3-month follow-up | 
| Shift rate of the painless shock impedance measurement |  | between 3- and 6-month follow-up |
Selective Use of Antibiotics in Neonates Born to Mothers With Suspected Chorioamnionitis

Study Overview
=================
Brief Summary
-----------------
Retrospective Chart Review to determine the selective use of antibiotics in neonates born to mothers with suspected chorioamnionitis

Detailed Description
-----------------
To determine the incidence and types of adverse outcomes in infants born to mothers with signs of chorioamnionitis when these infants are asymptomatic and are not treated with antibiotics empirically.

Official Title
-----------------
Selective Use of Antibiotics in Neonates Born to Mothers With Suspected Chorioamnionitis

Conditions
-----------------
Chorioamnionitis

Intervention / Treatment
-----------------
* Other: Retrospective Chart Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Mother/baby dyads in which the mother was diagnosed with chorioamnionitis and/or had intrapartum fever (as diagnosed by obstetrician) Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 35 Weeks
Maximum Age: 42 Weeks

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Retrospective Chart Review|Retrospective Chart Review|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infants born to mother with chorioamnionitis/intrapartum fever as assessed by chart review. | The retrospective chart review would analyze the total number of infants born to mothers with chorioamnionitis/intrapartum fever. | Infants born from July, 2012 to December 31, 2018. |
Does Statin Therapy Reduce Sympathoexcitation in Hypertension?

Study Overview
=================
Brief Summary
-----------------
A number of patients with hypertension have increased central sympathetic activity. Statins seem to inhibit central sympathetic output. This study assesses the effect of statins on central sympathetic activity in hypertension patients.

Official Title
-----------------
Does Statin Therapy Reduce Sympathoexcitation in Hypertension?

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: atorvastatin 80 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (Known) hypertension stable drug therapy for at least 2 months age 18-70 jaar BMI 18-35 kg/m2 Sinusrhythm Exclusion Criteria: Recent cardiovascular event <6 mnd Plasma Creatinin: female: >120 mmol/L male: >133 mmol/L use of: tricyclic antidepressants alpha-1 -and/or alpha-2 blockers disease of the autonomic nervous system (Parkinsons disease, Shy- Drager syndrome, etc) Albuminuria >300 mg/dag

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: atorvastatin 80 mg|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in central sympathetic activity |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in cholesterol levels, renin and aldosteron |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, statin, sympathetic
NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients

Study Overview
=================
Brief Summary
-----------------
NovellusDx technology identifies tumor-specific driver mutations, but unlike sequencing-based tests, NovellusDx has a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus. This allows NovellusDx to identify functionally-impactful driver mutations regardless of whether the mutation has previously been described or linked to a tumor type.

Official Title
-----------------
Collection of Lung Malignant Tissue for the Validation of a Novel Technology to Identify Oncogenic Mutations and Personalized Medicine

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that are suspected to have lung cancer and are eligible for biopsy, surgical intervention or pleural fluid suction Exclusion Criteria: Patients without lung cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correct identification of tumor mutant genes | Correct identification of patient oncogenic mutation in over 85% of the cases. this will be achieved by comparing sequencing results of the patient tumors to the results achieved using the NovellusDx diagnostic platform. | up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient diagnosed with lung cancer